Table 1.
Multinomial logistic regression of surveyed factors and preference for endoscopy or beta blocker first
| Factor | EGD first | BB first |
|---|---|---|
| Male | 0.96 (0.52–1.80) | 1.22 (0.56–2.67) |
| MELD-Na (per 1-point increase) | 0.98 (0.91–1.05) | 0.97 (0.88–1.06) |
| Had prior EGD (Yes) | 0.43 (0.08–2.21) | 0.11 (0.02–0.52)b |
| Had prior variceal bleed (Yes) | 0.94 (0.47–1.85) | 1.32 (0.58–2.98) |
| Had prior BB use (Yes) | 0.47 (0.25–0.89)b | 0.73 (0.33–1.60) |
| Self-assessed risk of variceal bleed (per 10% increase) | 0.95 (0.84–1.08) | 1.01 (0.86–1.18) |
| Want to avoid pills (per 1-point increasea) | 1.41 (1.08–1.85)b | 0.95 (0.69–1.30) |
| Want to avoid EGD (per 1-point increasea) | 0.63 (0.47–0.85)b | 1.40 (0.99–1.97) |
| Concerned about EGD risks (per 1-point increasea) | 0.74 (0.55–0.99) | 1.24 (0.89–1.75) |
| Concerned about BB risks (per 1-point increasea) | 1.56 (1.17–2.09)b | 1.05 (0.75–1.48) |
| Concerned about COVID risks (per 1-point increasea) | 0.86 (0.67–1.10) | 1.21 (0.89–1.65) |
| Want personalized recommendations (per 1-point increasea) | 1.12 (0.82–1.54) | 1.87 (1.16–3.01)b |
EGD, endoscopy (esophagogastroduodenoscopy); BB, beta blocker; MELD-Na, Model of End-stage Liver Disease-Sodium.
All values are presented as odds ratio followed by 95% confidential interval in parentheses; reference: neutral response.
a
Likert scale from 1 to 5 with 1 = strongly disagree, 3 = neutral, and 5 = strongly agree.
b
Denotes statistical significance.